

Icahn School of Medicine at Mount Sinai commences clinical testing with Seracam®

London, UK and New York, USA, 6 September 2023, Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing Seracam®, a portable hybrid gamma-optical camera for medical imaging, and the Icahn School of Medicine at Mount Sinai, a ground-breaking leader in medical education, today announce the start of clinical testing using the Seracam® camera.

The primary objective of this investigator sponsored study is to assess the correlation of images obtained using Seracam®, to those obtained with a current state-of-the-art gamma camera for nuclear medical imaging. The study is being led by Dr Munir Ghesani, System Chief of Nuclear Medicine at Mount Sinai Health, Associate Professor of Radiology at the Icahn School of Medicine at Mount Sinai, and immediate past President of the Society of Nuclear Medicine and Molecular Imaging.

The study will involve a comparison of the visualisation of radiopharmaceutical uptake between Seracam® and a standard gamma camera, using images obtained from a variety of imaging procedures, each taken from the same patient on the same day, across a group of 50 patients.

Dr Munir Ghesani, System Chief of Nuclear Medicine at Mount Sinai Health, commented:

“Gamma imaging is a powerful diagnostic tool, yet it is currently available exclusively to patients in a hospital’s nuclear imaging department, which is not always possible for either the patient or physician. Consequently, we are excited to have the opportunity to evaluate the potential for an alternative portable, small field-of-view camera, such as Seracam, in the clinic. This could enable the expansion of this important imaging modality to new patient populations.”

Mark Rosser, Chief Executive Officer of Serac Imaging Systems added:

“We are really excited to be working with Dr Ghesani and his team at the prestigious Mount Sinai hospital. Mount Sinai is the third clinical testing site to commence user studies with Seracam this year, and we are now looking forward to the generation of clinical images, as well as receiving feedback on the patient and clinician’s experience. By miniaturising molecular imaging technology into a compact and portable hybrid gamma-optical camera, we believe Seracam has real potential to improve workflow in nuclear medicine departments and reach new patient populations by enabling imaging in locations that are currently inaccessible.”

- ENDS -

For more information, please contact:

Serac Imaging Systems Ltd

www.seracimaging.com

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Notes to Editors**About Serac Imaging Systems and Seracam®**

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient’s bedside, instead of being confined for use in a hospital’s nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and

enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimaging.com

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.